Edgewise Therapeutics (EWTX) Depreciation & Amortization (CF) (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Depreciation & Amortization (CF) of $537000.0 for Q1 2026, up 4.68% on a YoY basis from $513000.0 in Q1 2025, and up 10.95% sequentially from $484000.0 in Q4 2025.
Edgewise Therapeutics (EWTX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $537000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 4.68% year-over-year to $537000.0; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 2.93% YoY), and the FY2025 full-year result was $2.1 million, up 0.72% from the prior year.
- Depreciation & Amortization (CF) grew to $537000.0 in Q1 2026, from $484000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $569000.0 in Q4 2024 to a low of $100000.0 in Q1 2022.
- A 5-year average of $380647.1 and a median of $484000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 400.0% in 2023 and slipped 14.94% in 2025, its largest moves.
- Tracing EWTX's Depreciation & Amortization (CF) over 5 years: stood at $100000.0 in 2022, then soared by 400.0% to $500000.0 in 2023, then rose by 13.8% to $569000.0 in 2024, then fell by 14.94% to $484000.0 in 2025, then grew by 10.95% to $537000.0 in 2026.
- Business Quant data shows EWTX's Depreciation & Amortization (CF) at $537000.0 in Q1 2026, $484000.0 in Q4 2025, and $500000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | 537,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 537,000.00 |
| Mar 31, 2026 | 537,000.00 |
| Dec 31, 2025 | 484,000.00 |
| Dec 31, 2025 | 484,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Dec 31, 2024 | 569,000.00 |
| Dec 31, 2024 | 569,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 473,000.00 |
| Mar 31, 2024 | 473,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |